These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7833464)

  • 21. Alloimmune refractoriness to platelet transfusions.
    Sandler SG
    Curr Opin Hematol; 1997 Nov; 4(6):470-3. PubMed ID: 9359008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects on recipients of exposure to allogeneic donor leukocytes.
    Dzik WH
    J Clin Apher; 1994; 9(2):135-8. PubMed ID: 7798162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness.
    Cid J; Magnano L; Acosta M; Alba C; Esteve J; Lozano M
    Platelets; 2015; 26(2):190-4. PubMed ID: 24867634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The challenge of platelet alloimmunization: management and prevention.
    Kickler TS
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of leukocyte-reduced blood components.
    Miller JP; Mintz PD
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):69-90. PubMed ID: 7737945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Leukocyte depletion of blood products and anti-HLA immunization].
    Valla A
    Rev Fr Transfus Hemobiol; 1993 Jun; 36(3):281-91. PubMed ID: 8347251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
    Eernisse JG; Brand A
    Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
    Hess JR; Trachtenberg FL; Assmann SF; Triulzi DJ; Kaufman RM; Strauss RG; Granger S; Slichter SJ
    Vox Sang; 2016 Oct; 111(3):281-291. PubMed ID: 27185561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of leukocyte-depleted platelet concentrates for prevention of HLA-alloimmunization in patients with frequent platelet transfusions: a prospective multi-institutional study using a polyester platelet filter].
    Handa M; Ikeda Y; Kurata Y; Tsubaki K; Horiuchi A; Furihata K; Kimura Y; Toyama K; Takamoto S; Tsukimoto I
    Rinsho Ketsueki; 1992 Apr; 33(4):451-60. PubMed ID: 1602608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
    Toor AA; Choo SY; Little JA
    Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedside filtration of blood products in the prevention of HLA alloimmunization--a prospective randomized study. Alloimmunisation Study Group.
    Williamson LM; Wimperis JZ; Williamson P; Copplestone JA; Gooi HC; Morgenstern GR; Norfolk DR
    Blood; 1994 May; 83(10):3028-35. PubMed ID: 8180400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunogenicity of white cell fragments in platelet concentrates.
    Navarrete C; Contreras M
    Vox Sang; 2006 Apr; 90(3):205; author reply 206. PubMed ID: 16507023
    [No Abstract]   [Full Text] [Related]  

  • 33. Human leucocyte antigen alloimmunization after bone marrow transplantation: an association with chronic myelogenous leukaemia.
    Geiger TL; Woodard P; Tong X; Srivastava DK; Johnson R; Turner V; Hale G; Richardson S
    Br J Haematol; 2002 Jun; 117(3):634-41. PubMed ID: 12028035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization.
    Murphy MF; Metcalfe P; Thomas H; Eve J; Ord J; Lister TA; Waters AH
    Br J Haematol; 1986 Mar; 62(3):529-34. PubMed ID: 3954967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies.
    Heddle NM
    Transfus Med Rev; 1994 Jan; 8(1):15-28. PubMed ID: 8136604
    [No Abstract]   [Full Text] [Related]  

  • 36. UVB irradiation of human platelet concentrates does not prevent HLA alloimmunization in recipients.
    Grijzenhout MA; Aarts-Riemens MI; de Gruijl FR; van Weelden H; van Prooijen HC
    Blood; 1994 Nov; 84(10):3524-31. PubMed ID: 7949107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.
    Andreu G; Dewailly J; Leberre C; Quarre MC; Bidet ML; Tardivel R; Devers L; Lam Y; Soreau E; Boccaccio C
    Blood; 1988 Sep; 72(3):964-9. PubMed ID: 3416079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of idiopathic myelofibrosis with alloimmunization to HLA-identical platelet transfusions not responsive to antibody absorption over protein-A columns.
    Menicucci A; Di Pietro G; Venturini S; Avanzi G
    Transfus Sci; 1995 Dec; 16(4):391-5. PubMed ID: 10159510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.